In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.
Mona O MohsenMatthew HeathMatthias F KramerThalia Carreno VelazquezAlan BullimoreMurray A SkinnerDaniel E SpeiserMartin F BachmannPublished in: Journal for immunotherapy of cancer (2022)
Our new immune-enhancer turned immunologically cold tumors into hot ones and inhibited local and distant tumor growth. This type of immunotherapy does not require the identification of (patient-individual) relevant tumor antigens. It is well tolerated, non-infectious, and affordable, and can readily be upscaled for future clinical testing and broad application in melanoma and likely other solid tumors.